Benedetta Albieri
Herlev, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.
Journal: Journal for immunotherapy of cancer
Published: July 27, 2026
Fresh-blood immune profiling of immune-related adverse events in real-world patients identifies organ-specific and steroid responsiveness signatures.
Journal: Immuno-oncology technology
Published: April 20, 2026
Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma.
Journal: Immuno-oncology technology
Published: January 13, 2025
Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.
Journal: Cell reports. Medicine
Published: August 29, 2024
Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.
Journal: Journal for immunotherapy of cancer
Published: May 01, 2024
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma.
Journal: Oncoimmunology
Published: December 21, 2023
Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 21, 2022
First in man study: Bcl-Xl_42-CAF®09b vaccines in patients with locally advanced prostate cancer.
Journal: Frontiers in immunology
Published: December 13, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026